GEAN — Genetic Analysis As Cashflow Statement
0.000.00%
Last trade - 00:00- NOK51.47m
- NOK33.96m
- NOK15.89m
- 44
- 20
- 36
- 20
Annual cashflow statement for Genetic Analysis As, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.1 | -29 | -28.3 | -23.8 | -14.8 |
| Depreciation | |||||
| Non-Cash Items | 3.3 | -3.15 | 2.73 | -0.89 | 2.46 |
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.08 | -0.017 | 1.26 | 1.9 | -1.43 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -6.56 | -27.6 | -19.5 | -17.2 | -8.5 |
| Capital Expenditures | -5.18 | -1.95 | -0.227 | -0.643 | -1.95 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0.018 | — | -0.5 | -0.1 |
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5.18 | -1.94 | -0.227 | -1.14 | -2.05 |
| Financing Cash Flow Items | — | — | — | — | -0.289 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 31.9 | 52.2 | -1.8 | 9.34 | 7.63 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 20.2 | 22.6 | -21.5 | -9.03 | -2.92 |